Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02238847 · ClinicalTrials.gov registry record · NA
Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 119
- Enrollment target
NCT02238847 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 119 participants.
The verdict
NCT02238847, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 119 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate non-inferiority of Fully Covered biliary SEMS to Uncovered biliary SEMS in biliary drainage for the pre-operative management of biliary obstructive symptoms caused by pancreatic cancer in patients undergoing neoadjuvant therapy.
Interventions
- DEVICE WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2015-03-24 |
| Est. Completion | 2018-04-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02238847
The ClinicalTrials.gov registry entry for NCT02238847 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WallFlex™ Biliary RX Fully Covered/Uncovered Stent System is the first listed.
NCT02238847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02238847 about?
NCT02238847 is a clinical study titled "Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy". The purpose of this study is to demonstrate non-inferiority of Fully Covered biliary SEMS to Uncovered biliary SEMS in biliary drainage for the pre-operative management of biliary obstructive symptoms caused by pancreatic cancer in patients undergoing neoadjuvant therapy.
What is the current status of trial NCT02238847?
This trial is currently completed. It is a NA study. The enrollment target is 119 participants. The study started on 2015-03-24. Estimated completion is 2018-04-10.
What interventions are being tested in trial NCT02238847?
The interventions under investigation include: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System (DEVICE).
Who is sponsoring clinical trial NCT02238847?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.